BAJAJ BROKING
IOL Chemicals and Pharmaceuticals will consider a stock split at its board meeting on December 27. Despite recent growth of 16% in a month, the IOL Chemicals and Pharmaceuticals share price remains 12% lower year-on-year.
IOL Chemicals and Pharmaceuticals Ltd. has announced a board meeting on December 27, 2024, to discuss a potential stock split. The company plans to alter its share capital by subdividing its fully paid-up equity shares of ₹10 face value, aiming to enhance liquidity and affordability for investors.
Also read: F.I.L.A. to Sell 4.57% Stake in DOMS via Block Deal at ₹2,755/Sh
Meeting date: December 27, 2024.
Proposed action: Subdivision/split of ₹10 face value equity shares.
Objective: Increase affordability and liquidity in the stock market.
Current performance: Share price dropped 3.17% on December 18, closing at ₹405.95.
Also read: Yatharth Hospital Opens QIP with Floor Price at ₹626
IOL Chemicals and Pharmaceuticals share price closed at ₹405.95, marking a 3.17% decline on December 18. Despite this, the stock has risen over 16% in the past month, outperforming the Nifty50 index, which gained just over 3% during the same period. However, the one-year return on the stock remains negative, down nearly 12%.
Metrics | Value |
Last closing price | ₹405.95 |
Monthly performance | +16% |
Yearly performance | -12% |
Nifty50 one-month performance | +3% |
In Q2 FY24, the company reported consolidated net sales of ₹525.75 crore, a 3.59% decline year-on-year. Net profit dropped by 49.43% to ₹19.15 crore compared to ₹37.87 crore in Q2 FY23. EBITDA also declined by 32.69%, reflecting market challenges.
Metric | Q2 FY24 | Q2 FY23 | Change |
Net Sales | ₹525.75 Cr | ₹545.30 Cr | -3.59% |
Net Profit | ₹19.15 Cr | ₹37.87 Cr | -49.43% |
EBITDA | ₹48.00 Cr | ₹71.31 Cr | -32.69% |
The planned stock split reflects IOL Chemicals’ efforts to make its shares more accessible to retail investors. This move is expected to improve market participation and liquidity while supporting the company’s growth aspirations in therapeutic areas such as pain management, anti-diabetes, and antihypertensive segments.
The stock split discussion by IOL Chemicals and Pharmaceuticals demonstrates its intent to enhance shareholder value and market accessibility. Investors will closely watch the December 27 board meeting for further developments.
Also read: Zaggle Prepaid Launches QIP at ₹550.73/Share Floor Price
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading